Progenics Pharmaceuticals Inc. (PGNX) fell the most in 14 months after a study summary showed two patients died of sepsis in a trial of the company’s experimental prostate cancer treatment. Progenics tumbled 19 percent to $5.04 at 12:11 p.m. New York time, after losing as much as 20 percent for its biggest intraday drop since November 2012. The Tarrytown, New York-based company’s stock had doubled in the 12 months through yesterday.
Help employers find you! Check out all the jobs and post your resume.
